Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 997 to 1001 of 1001 entries
Sorted by: Best Match Show Resources per page
Treatments for COVID-19: Lessons from 2020 and new therapeutic options.

Current opinion in pharmacology

Salasc F, Lahlali T, Laurent E, Rosa-Calatrava M, Pizzorno A.
PMID: 34915400
Curr Opin Pharmacol. 2021 Nov 18;62:43-59. doi: 10.1016/j.coph.2021.11.002. Epub 2021 Nov 18.

To face the COVID-19 pandemic, prophylactic vaccines have been developed in record time, but vaccine coverage is still limited, accessibility is not equitable worldwide, and the vaccines are not fully effective against emerging variants. Therefore, therapeutic treatments are urgently...

Cite
Salasc F, Lahlali T, Laurent E, et al. Treatments for COVID-19: Lessons from 2020 and new therapeutic options. Curr Opin Pharmacol. 2021;62:43-59doi: 10.1016/j.coph.2021.11.002.
Salasc, F., Lahlali, T., Laurent, E., Rosa-Calatrava, M., & Pizzorno, A. (2021). Treatments for COVID-19: Lessons from 2020 and new therapeutic options. Current opinion in pharmacology, 6243-59. https://doi.org/10.1016/j.coph.2021.11.002
Salasc, Fanny, et al. "Treatments for COVID-19: Lessons from 2020 and new therapeutic options." Current opinion in pharmacology vol. 62 (2021): 43-59. doi: https://doi.org/10.1016/j.coph.2021.11.002
Salasc F, Lahlali T, Laurent E, Rosa-Calatrava M, Pizzorno A. Treatments for COVID-19: Lessons from 2020 and new therapeutic options. Curr Opin Pharmacol. 2021 Nov 18;62:43-59. doi: 10.1016/j.coph.2021.11.002. Epub 2021 Nov 18. PMID: 34915400; PMCID: PMC8598952.
Copy Download .nbib Format: NLM
Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.

Cell cycle (Georgetown, Tex.)

Maskey RS, Wang F, Lehman E, Wang Y, Emmanuel N, Zhong W, Jin G, Abraham RT, Arndt KT, Myers JS, Mazurek A.
PMID: 33356791
Cell Cycle. 2021 Jan;20(1):65-80. doi: 10.1080/15384101.2020.1859195. Epub 2020 Dec 28.

Palbociclib, a selective CDK4/6 kinase inhibitor, is approved in combination with endocrine therapies for the treatment of advanced estrogen receptor positive (ER+) breast cancer. In pre-clinical cancer models, CDK4/6 inhibitors act primarily as cytostatic agents. In two commonly studied...

Cite
Maskey RS, Wang F, Lehman E, et al. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. Cell Cycle. 2020;20(1):65-80doi: 10.1080/15384101.2020.1859195.
Maskey, R. S., Wang, F., Lehman, E., Wang, Y., Emmanuel, N., Zhong, W., Jin, G., Abraham, R. T., Arndt, K. T., Myers, J. S., & Mazurek, A. (2021). Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. Cell cycle (Georgetown, Tex.), 20(1), 65-80. https://doi.org/10.1080/15384101.2020.1859195
Maskey, Reeja S, et al. "Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells." Cell cycle (Georgetown, Tex.) vol. 20,1 (2021): 65-80. doi: https://doi.org/10.1080/15384101.2020.1859195
Maskey RS, Wang F, Lehman E, Wang Y, Emmanuel N, Zhong W, Jin G, Abraham RT, Arndt KT, Myers JS, Mazurek A. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. Cell Cycle. 2021 Jan;20(1):65-80. doi: 10.1080/15384101.2020.1859195. Epub 2020 Dec 28. PMID: 33356791; PMCID: PMC7849761.
Copy Download .nbib Format: NLM
Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations.

International journal of radiation oncology, biology, physics

Lin SH, Willers H, Krishnan S, Sarkaria JN, Baumann M, Lawrence TS.
PMID: 34454045
Int J Radiat Oncol Biol Phys. 2021 Dec 01;111(5):1131-1139. doi: 10.1016/j.ijrobp.2021.08.018. Epub 2021 Aug 25.

Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation...

Cite
Lin SH, Willers H, Krishnan S, et al. Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. Int J Radiat Oncol Biol Phys. 2021;111(5):1131-1139doi: 10.1016/j.ijrobp.2021.08.018.
Lin, S. H., Willers, H., Krishnan, S., Sarkaria, J. N., Baumann, M., & Lawrence, T. S. (2021). Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. International journal of radiation oncology, biology, physics, 111(5), 1131-1139. https://doi.org/10.1016/j.ijrobp.2021.08.018
Lin, Steven H, et al. "Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations." International journal of radiation oncology, biology, physics vol. 111,5 (2021): 1131-1139. doi: https://doi.org/10.1016/j.ijrobp.2021.08.018
Lin SH, Willers H, Krishnan S, Sarkaria JN, Baumann M, Lawrence TS. Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. Int J Radiat Oncol Biol Phys. 2021 Dec 01;111(5):1131-1139. doi: 10.1016/j.ijrobp.2021.08.018. Epub 2021 Aug 25. PMID: 34454045.
Copy Download .nbib Format: NLM
Current status in the discovery of dual BET/HDAC inhibitors.

Bioorganic & medicinal chemistry letters

Ren Q, Gao W.
PMID: 33685790
Bioorg Med Chem Lett. 2021 Apr 15;38:127829. doi: 10.1016/j.bmcl.2021.127829. Epub 2021 Mar 05.

The development of desired multitarget agents may provide an attractive and cost-effective complement or alternative to drug combinations. Bromodomain and extraterminal domain (BET) and histone deacetylase (HDAC), as important epigenetic modulators, are attractive targets in drug discovery and development....

Cite
Ren Q, Gao W. Current status in the discovery of dual BET/HDAC inhibitors. Bioorg Med Chem Lett. 2021;38:127829doi: 10.1016/j.bmcl.2021.127829.
Ren, Q., & Gao, W. (2021). Current status in the discovery of dual BET/HDAC inhibitors. Bioorganic & medicinal chemistry letters, 38127829. https://doi.org/10.1016/j.bmcl.2021.127829
Ren, Qinghua, and Gao, Wenqian. "Current status in the discovery of dual BET/HDAC inhibitors." Bioorganic & medicinal chemistry letters vol. 38 (2021): 127829. doi: https://doi.org/10.1016/j.bmcl.2021.127829
Ren Q, Gao W. Current status in the discovery of dual BET/HDAC inhibitors. Bioorg Med Chem Lett. 2021 Apr 15;38:127829. doi: 10.1016/j.bmcl.2021.127829. Epub 2021 Mar 05. PMID: 33685790.
Copy Download .nbib Format: NLM
Long-Term Analysis of Clinical Features and Treatment Outcomes of Inflammatory Choroidal Neovascularization.

American journal of ophthalmology

Kim M, Lee J, Park YG, Park YH.
PMID: 34298010
Am J Ophthalmol. 2021 Jul 21;233:18-29. doi: 10.1016/j.ajo.2021.07.014. Epub 2021 Jul 21.

PURPOSE: To investigate the long-term clinical features and treatment outcomes of patients with inflammatory choroidal neovascularization (CNV) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF).DESIGN: Retrospective, interventional, consecutive case series.METHODS: Sixty-five eyes of 65 patients with inflammatory CNV treated...

Cite
Kim M, Lee J, Park YG, et al. Long-Term Analysis of Clinical Features and Treatment Outcomes of Inflammatory Choroidal Neovascularization. Am J Ophthalmol. 2021;233:18-29doi: 10.1016/j.ajo.2021.07.014.
Kim, M., Lee, J., Park, Y. G., & Park, Y. H. (2021). Long-Term Analysis of Clinical Features and Treatment Outcomes of Inflammatory Choroidal Neovascularization. American journal of ophthalmology, 23318-29. https://doi.org/10.1016/j.ajo.2021.07.014
Kim, Mirinae, et al. "Long-Term Analysis of Clinical Features and Treatment Outcomes of Inflammatory Choroidal Neovascularization." American journal of ophthalmology vol. 233 (2021): 18-29. doi: https://doi.org/10.1016/j.ajo.2021.07.014
Kim M, Lee J, Park YG, Park YH. Long-Term Analysis of Clinical Features and Treatment Outcomes of Inflammatory Choroidal Neovascularization. Am J Ophthalmol. 2021 Jul 21;233:18-29. doi: 10.1016/j.ajo.2021.07.014. Epub 2021 Jul 21. PMID: 34298010.
Copy Download .nbib Format: NLM
Showing 997 to 1001 of 1001 entries